{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:30:33Z","timestamp":1790137833229,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006012","name":"Christian Doppler Research Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Chemical Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106939","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:10:35Z","timestamp":1774959035000},"page":"106939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive\/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1742-9271","authenticated-orcid":false,"given":"N.","family":"Dobri\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9401-5224","authenticated-orcid":false,"given":"S.O.","family":"Hasenleithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Suppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.","family":"Klocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1009-3777","authenticated-orcid":false,"given":"D.","family":"Hlauschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0209-7315","authenticated-orcid":false,"given":"R.","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Beichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3798-6833","authenticated-orcid":false,"given":"C.","family":"Albertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0283-8176","authenticated-orcid":false,"given":"D.","family":"Egle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Starzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-6917","authenticated-orcid":false,"given":"R.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-0920","authenticated-orcid":false,"given":"T.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rinnerthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-0362","authenticated-orcid":false,"given":"P.J.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Heitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9093-0743","authenticated-orcid":false,"given":"N.","family":"Dandachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9482-9191","authenticated-orcid":false,"given":"M.","family":"Balic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.106939_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106939_bib2","first-page":"524","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2026.106939_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ctrv.2017.12.002","article-title":"Ongoing unmet needs in treating estrogen receptor-positive\/HER2-negative metastatic breast cancer","volume":"63","author":"Ba\u015faran","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2026.106939_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.breast.2018.10.001","article-title":"Targeting CDK4\/6 pathways and beyond in breast cancer","volume":"43","author":"Ribnikar","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2026.106939_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1075830","article-title":"Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC","volume":"13","author":"Tang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41523-024-00626-6","article-title":"Circulating tumor DNA validity and potential uses in metastatic breast cancer","volume":"10","author":"Amato","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106939_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31722","article-title":"Circulating tumor DNA and survival in metastatic breast cancer: a systematic review and meta-analysis","volume":"7","author":"Dickinson","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106939_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106939_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tig.2023.01.004","article-title":"Bridging biological cfDNA features and machine learning approaches","volume":"39","author":"Moser","year":"2023","journal-title":"Trends Genet"},{"key":"10.1016\/j.esmoop.2026.106939_bib10","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/1878-0261.13671","article-title":"Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression","volume":"19","author":"Klocker","year":"2025","journal-title":"Mol Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106939_bib11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106939_bib12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2026.106939_bib13","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2026.106939_bib14","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2\u2212 metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106939_bib15","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106939_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106939_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2026.106939_bib18","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.annonc.2025.06.015","article-title":"Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive\/HER2-negative breast cancer","volume":"36","author":"Mamann","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106939_bib19","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1038\/s41591-025-03935-w","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial","volume":"31","author":"Jongbloed","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41523-025-00802-2","article-title":"Circulating genomic landscape following cyclin-dependent kinase 4\/6 inhibitors exposure in HR+\/HER2\u2212 metastatic breast cancer: a retrospective multi-institutional consortium analysis","volume":"11","author":"Pontolillo","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41523-025-00783-2","article-title":"Personalized ctDNA monitoring in metastatic HR+\/HER2\u2212 breast cancer patients during endocrine and CDK4\/6 inhibitor therapy","volume":"11","author":"Fuentes-Antr\u00e1s","year":"2025","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41523-025-00805-z","article-title":"Clinical impact of single-gene vs. panel sequencing in advanced HR+\/HER2\u2212 breast cancer: insights and implications","volume":"11","author":"Klocker","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.106939_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106939_bib24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41416-021-01601-9","article-title":"Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients","volume":"126","author":"Suppan","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.106939_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106939_bib26","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1373\/clinchem.2014.234286","article-title":"Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach","volume":"61","author":"Belic","year":"2015","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106939_bib27","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3390\/cancers11081171","article-title":"Untargeted assessment of tumor fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment","volume":"11","author":"Suppan","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106939_bib28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106939_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106939_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.esmoop.2026.106939_bib31","series-title":"Selected Papers of Hirotugu Akaike","first-page":"199","article-title":"Information theory and an extension of the maximum likelihood principle","author":"Akaike","year":"1998"},{"key":"10.1016\/j.esmoop.2026.106939_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231175440","article-title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","volume":"15","author":"Yang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106939_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jnci\/djaa087","article-title":"Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer","volume":"113","author":"O\u2019Leary","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106939_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411419","article-title":"Real-world use of highly sensitive liquid biopsy monitoring in metastatic breast cancer patients treated with endocrine agents after exposure to aromatase inhibitors","volume":"24","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12916-023-03017-z","article-title":"Potential value of ctDNA monitoring in metastatic HR+\/HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial","volume":"21","author":"Chiu","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.esmoop.2026.106939_bib36","article-title":"Cyclin-dependent kinase 4\/6 inhibitors beyond progression in metastatic breast cancer: a retrospective real-world biomarker analysis","volume":"7","author":"Gerratana","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106939_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002201","article-title":"Mutational profile of metastatic breast cancers: a retrospective analysis","volume":"13","author":"Lefebvre","year":"2016","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbae034","article-title":"Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact","volume":"8","author":"Huebner","year":"2025","journal-title":"Precis Clin Med"},{"key":"10.1016\/j.esmoop.2026.106939_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115739","article-title":"Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer","volume":"228","author":"Valenza","year":"2025","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106939_bib40","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1158\/1078-0432.CCR-22-2177","article-title":"Genomic complexity predicts resistance to endocrine therapy and CDK4\/6 inhibition in hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer","volume":"29","author":"Davis","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7757","key":"10.1016\/j.esmoop.2026.106939_bib41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic characterization of metastatic breast cancers","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41523-022-00426-w","article-title":"Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer","volume":"8","author":"Li","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106939_bib43","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/0008-5472.CAN-20-1200","article-title":"Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR1-mutant breast cancer","volume":"81","author":"Williams","year":"2021","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106939_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103731","article-title":"Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations","volume":"9","author":"Boscolo Bielo","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13046-025-03328-4","article-title":"A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development","volume":"44","author":"Guigal-Stephan","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","article-title":"Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study","volume":"34","author":"Reichert","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106939_bib47","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.106939_bib48","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.annonc.2025.08.911","article-title":"487MO Overall survival with first versus second-line use of CDK4\/6 inhibitors in HR+\/HER2\u2212 advanced breast cancer","volume":"36","author":"Wortelboer","year":"2025","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106939_bib49","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106939_bib50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdy497","article-title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","volume":"30","author":"Sokol","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106939_bib51","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106939_bib52","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41416-024-02804-6","article-title":"Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4\/6 inhibitors","volume":"131","author":"Sablin","year":"2024","journal-title":"Br J Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:32:52Z","timestamp":1776699172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008811"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106939","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive\/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106939"}}